Prediction models for rheumatoid arthritis during diagnostic investigation: Evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope

Annals of the Rheumatic Diseases

Volumn 66, Issue 3, 2007, Pages 364-369

  Vander Cruyssen, Bert ^a   Hoffman, Ilse E A ^a   Peene, Isabelle ^a   Union, Ann ^b   Mielants, Herman ^a   Meheus, Lydie ^b   De Keyser, Filip ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b INNOGENETICS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD45 ANTIGEN; CITRULLINE; EPITOPE; PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; ANTIBODY DETECTION; ARTHRALGIA; ARTICLE; CONNECTIVE TISSUE DISEASE; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; FEMALE; FIBROMYALGIA; HLA TYPING; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONARTICULAR RHEUMATISM; OSTEOARTHRITIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; STATISTICAL ANALYSIS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; EPIDEMIOLOGIC METHODS; EPITOPES; FEMALE; HISTOCOMPATIBILITY TESTING; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS; RHEUMATOID FACTOR;

EID: 34147219949     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.053470     Document Type: Article

References (37)

1. Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M. The effect of treatment on radiological progression of rheumatoid arthritis: a systematic review of randomised placebo-controlled trials. Rheumatology (Oxford) 2003;42:6-13.
2. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
3. Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 2004;4:239-62.
4. De Rycke L, Peene I, Hoffman IEA, Kruithof E, Union A, Meheus L, et al. Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63:1587-93.
5. Söderlin MK, Kastbom A, Kautiainen H, Leirisalo-Repo M, Strandberg G, Skogh T. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol 2004;33:185-8.
6. Union A, Meheus L, Humbel RL, Conrad K, Steiner G, Moereels H, et al. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum 2002;46:1185-95.
7. Schellekens GA, Visser H, de Jong BAW, van den Hoogen FHJ, Hazes JMW, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
8. Nogueira L, Chapuy-Regaud S, Constantin A, Gavel C, Sebbag M, Cantagrel A, et al. Autoantibodies to deiminated fibrinogen are the most efficient serological criterion for early rheumatoid arthritis diagnosis. Arthritis Res Ther 2003;5:S6.
9. Nielen M, van der Horst A, van Schaardenburg D, van der Horst-Bruinsma I, van de Stadt R, Aarden L, et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and protnostic value in early arthritis. Ann Rheum Dis 2005;64:1199-204.
10. Winchester R, Dwyer E, Rose S. The genetic basis of rheumatoid arthritis. The shared epitope hypothesis. Rheum Dis Clin North Am 1992;18:761-83.
11. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
12. Nell V, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis, 2005.Epub ahead of print..
13. Kroot EJ, De Jong BAW, Van Leeuwen MA, Swinkels H, Van den Hoogen FHJ, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
14. Jansen A, van der Horst-Bruinsma IE, van Schaardenburg D, van de Stadt RJ, de Koning MHMT, Dijkmans BAC. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002;29:2074-6.
15. Hoffman IEA, Peene I, Pottel H, Union A, Hulstaert F, Meheus L, et al. Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies and the HLA shared epitope for the diagnosis of rheumatoid arthritis. Clin Chem 2005;51:261-3.
16. Agresti A. An introduction to categocial data analysis. New York: John Wiley and Sons, 1996.
17. Halpern EF, Gazelle GS. Probability in radiology. Radiology 2003;226:12-15.
18. Kamoun M. Diagnostic performance and predictive value of anti-citrullinated peptide antibodies for diagnosis of rheumatoid arthritis: toward more accurate detection? Clin Chem 2005;51:12-13.
19. Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004;63:1079-84.
20. Landewe R, van der Heijde D. Radiographic progression depicted by probability plots: presenting data with optimal use of individual values. Arthritis Rheum 2004;50:699-706.
21. van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004;50:2113-21.
22. De Rycke L, Nicholas A, Cantaert T, Kruithof E, Echols JD, Vandekerckhove B, et al. Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase are pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity. Arhtiris Rheum 2005;52:2323-30.
23. Sebbag M, Chapuy-Regaud S, Auger I, Petit-Texeira E, Clavel C, Nogueira L, et al. Clinical and pathophysiological significance of the autoimmune response to citrullinated proteins in rheumatoid arthritis. Jt Bone Spine 2004;71:493-502.
24. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;15:538- 41.
25. Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006;45:478-80.
26. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-8.
27. Linn-Rasker SP, van der Helm-van Mil AH, Van Gaalen FA, Kloppenburg M, de Vries R, le Cessie S, et al. Smoking is a risk factor for anti-CCP antibodies only in RA patients that carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006;65:366-71.
28. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology or rheumatoia arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38-46.
29. Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004;6:R303-8.
30. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arhthritis in patients with undifferentiated arthritis. A prospective cohort study. Arthritis Rheum 2004;50:709-15.
31. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
32. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003;56:1129-35.
33. Bellman R. "Curse of dimensionality". Adaptive control processes: a guided tour, Princeton, NJ; Princeton University Press, 1961.
34. Van Looy S, Meeus J, Wyns B, Vander Cruyssen B, Boullart L, De Keyser F. "Comparison of Machine Learning models for prediction of dose increase in patients with rheumatoid arthritis." Proceedings of the Ninth International Conference on Engineering Applications of Neural Networks (EANN05), 24-26 August 2005, Lille, France, 189-96.
35. Symmons DP, Ollier WE, Brennan P, Silman AJ. Should patients with recent onset rheumatoid arthritis be offered genetic screening? Ann Rheum Dis 1996;55:407-10.
36. Van Loay S, Meeus J, Wyns B, Vander Conyssen B, Boullart L, De Keyser F. Comparison of machine learning models for prediction of dose increase in patients with rheumatoid arthritis. Proceedings of The Ninth International Conference on Engineering Applications of Neural Networks, (EANN05), Lille, France: 189-96. (24-26 Aug 2006).
37. Symmons DP, Ollier WE, Brennan P, Silman AJ. Should patients with recent onset rheumatoid arthritis be offered genetic screening? Ann Rheum Dis 1996;55:407-10.